Overview

Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, phase I study.
Phase:
Phase 1
Details
Lead Sponsor:
RemeGen Co., Ltd.